VantAI deep-learning collaborations with Janssen, Boehringer Ingelheim and Blueprint Medicines

Roivant said its subsidiaries Proteovant Therapeutics and VantAI had entered research collaborations on protein degraders and E3 ligase platforms. VantAI and Janssen Pharmaceutica will use VantAI's geometric deep learning platform, which generates degrader candidates for two disease targets. VantAI and Boehringer Ingelheim will use that platform to design degrader molecules. The Proteovant collaboration with Blueprint Medicines brings in VantAI's artificial intelligence technologies for degrader generation and optimization. The release says the Blueprint, Janssen and Boehringer Ingelheim collaborations include aggregate contingent milestone payments of over $1 billion as well as product royalties.